findmyKOL
Clinical trialNCT06030258RecruitingPhase 1/PHASE2Interventional

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

SponsorInxMed (Shanghai) Co., Ltd.Enrollment120Small Cell Lung Cancer Extensive Stage
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Shandong Province Cancer Hospital

    Jinan, China

    Recruiting
  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China

    Not, yet, recruiting
  • Henan Provincial People'S Hospital

    Zhengzhou, China

    Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Oct 2023
Primary completion
24 Dec 2025
Completion
24 Dec 2025
Last update posted
30 Apr 2025
Registered enrollment
120
Registry id
NCT06030258

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.